Komori
OLBA DVx HEALTHCARE (2689) · InitiativeDetermining the bonus factor to reflect failure to meet the operating profit budget

Introducing performance-linked bonuses and delegating decisions to the nomination and compensation committee

First written in FY2021. 7 of 12 entries say "Advanced", first in FY2022-Q1. Latest entry: FY2026.

12entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2022-Q1 – FY2023-Q3AdvancedFY2024-Q2 – FY2024OtherFY2025-H1 – FY20262021: 220212022: 320222023: 220232024: 220242025: 120252026: 22026
Same theme, other companies
Performance Targets as Conditions for Payment of Performance-Linked CompensationA theme 84 companies write about · 3 as a headwind · 71 as a tailwind

The whole theme swung hardest in 2020: 4 of 31 companies on the "Worse" side.

17 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 84 companies compared. The sentences above are computed from all 84.
Full recordFilings, disclosures and news, newest first
  1. FY2026Determining the bonus factor to reflect failure to meet the operating profit budgetAnnual report

    「The previous year's actual operating profit was ¥1,979 million, the operating profit budget was ¥2,000 million, representing 101.0% of the previous year's actual operating profit, and the current year's actual operating profit was ¥1,679 million, representing a budget achievement rate of 84.0%. In addition, the actual engagement score was slightly below the previous year's result. The coefficient was determined based on these figures.」

    For the short-term performance-linked compensation, the bonus coefficient for the current fiscal year was determined based on indicators including an operating profit budget achievement rate of 84.0% and an engagement score below the previous year's result.
  2. FY2026-H1Continued recognition of the provision for directors’ bonusesAnnual report

    「Provision for directors’ bonuses - 11,064」

    The operation of the short-term performance-linked compensation continues to be reflected in accounting as a ¥11.064 million provision for directors’ bonuses at the end of the interim accounting period.
  3. FY2025-H1RestatedAnnual report

    「Provision for directors’ bonuses 9,519」

    The operation of the short-term performance-linked compensation continues to be reflected in accounting as a ¥9.519 million provision for directors’ bonuses at the end of the interim period.
  4. FY2024AdvancedAnnual report

    「For the fiscal year, the previous year's actual operating profit was ¥2,151 million, the operating profit budget was ¥2,200 million, representing 102.2% of the previous year's operating profit, and the current year's actual operating profit was ¥2,226 million, representing a budget achievement rate of 101.2%. The coefficient was determined based on these figures.」

    For the short-term performance-linked compensation, the bonus coefficient was determined based on operating profit of 102.2% of the previous year's actual result and a budget achievement rate of 101.2%.
  5. FY2024-Q2AdvancedAnnual report

    「Provision for directors’ bonuses - 6,928」

    The operation of the short-term performance-linked compensation is reflected in accounting as a ¥6.928 million provision for directors’ bonuses at the end of the second quarter.
  6. FY2023ReframedAnnual report

    「At a meeting of the Board of Directors held on 30 June 2023, the company resolved to revise the “Policy for Determining the Content of Individual Directors’ Compensation and Other Remuneration” described in ②イ below, with a change to the coefficient used to calculate short-term performance-linked compensation (bonuses) as the principal change. The revised policy is as follows.」

    The company revised its policy to change the coefficient used to calculate short-term performance-linked compensation. For FY2023 bonuses, the indicators used were actual net sales of ¥110.472 billion against a target of ¥109.479 billion, and actual ordinary profit of ¥2.158 billion against a target of ¥1.998 billion.
  7. FY2023-Q3AdvancedAnnual report

    「Provision for directors’ bonuses - 9,987」

    The operation of the short-term performance-linked compensation is reflected in accounting as a ¥9.987 million provision for directors’ bonuses at the end of the third quarter.
  8. FY2023-Q1AdvancedAnnual report

    「Provision for directors’ bonuses - 3,329」

    The operation of the short-term performance-linked compensation is reflected in accounting as a ¥3.329 million provision for directors’ bonuses at the end of the first quarter.
  9. FY2022-Q3AdvancedAnnual report

    「Provision for directors’ bonuses - 12,564」

    The provision for directors’ bonuses increased from ¥8.376 million at the end of the second quarter to ¥12.564 million at the end of the third quarter, continuing to reflect in accounting the operation of the short-term performance-linked compensation introduced in the previous fiscal year.
  10. FY2022-Q2AdvancedAnnual report

    「Provision for directors’ bonuses - 8,376」

    The provision for directors’ bonuses, which had not been recorded at the end of the previous consolidated fiscal year, increased from ¥4.188 million at the end of the first quarter to ¥8.376 million. The operation of the short-term performance-linked compensation introduced in the previous fiscal year continues to be reflected as an accounting provision.
  11. FY2022-Q1AdvancedAnnual report

    「Provision for directors’ bonuses - 4,188」

    The company recorded a ¥4.188 million provision for directors’ bonuses at the end of the first quarter, although none had been recorded at the end of the previous consolidated fiscal year. The operation of the short-term performance-linked compensation introduced in the previous fiscal year is reflected as an accounting provision.
  12. FY2021First statedAnnual report

    「At a meeting of the Board of Directors held on 30 June 2021, the company resolved to revise the “Policy for Determining the Content of Individual Directors’ Compensation and Other Remuneration” described in ②イ below, with the introduction of short-term performance-linked compensation (bonuses) and the delegation to the Nomination and Compensation Committee of decisions on the details of individual directors’ compensation and other remuneration as the principal changes. The revised policy is as follows. Bonuses use annual indicators such as net sales and ordinary profit so that they function as short-term incentives. For directors other than the Representative Director and President and the Vice Chairman, separate indicators are also established based on the relevant targets, so that the bonuses serve as incentives to achieve targets set according to each director’s responsibilities under the medium-term management plan.」

    The company newly introduced short-term performance-linked compensation (bonuses), using annual indicators such as net sales and ordinary profit. The framework was revised to include the delegation of decisions on individual directors’ compensation to the Nomination and Compensation Committee, chaired by an outside director.
Moved together

"Expanding the medical equipment business with consumables as a growth driver" moved the same way as this thread, in the same document, in 7 of its 12 moves.

775444★123456
  1. ★This thread
  2. 1Expanding the medical equipment business with consumables as a growth driver7×
  3. 2Expanding the customer base, centered on home-care rentals7×
  4. 3Expanding orders for large-scale equipment and modalities5×
  5. 4Coexistence of sales growth and profit decline4×
  6. 5Deepening mature fields and developing new areas of healthcare4×
  7. 6Business Impact of the COVID-19 Pandemic4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
OLBA DVx HEALTHCARE's next results are scheduled for 2026-10-30. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Introducing performance-linked bonuses and delegating decisions to the nomination and compensation committee | OLBA DVx HEALTHCARE,Inc. (2689) | Komori